Compare ADPT & SLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | SLG |
|---|---|---|
| Founded | 2009 | 1980 |
| Country | United States | United States |
| Employees | N/A | 1289 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2019 | N/A |
| Metric | ADPT | SLG |
|---|---|---|
| Price | $14.25 | $42.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 19 |
| Target Price | $17.78 | ★ $50.63 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-05-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 7.29% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $8.38 | $34.77 |
| 52 Week High | $20.76 | $66.91 |
| Indicator | ADPT | SLG |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 57.81 |
| Support Level | $12.22 | $35.66 |
| Resistance Level | $15.38 | $44.71 |
| Average True Range (ATR) | 0.62 | 1.74 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 50.26 | 63.46 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.